Gut microbiota, microbial metabolites, and mucosal barrier dysfunction in benign anorectal disorders and ulcerative colitis: shared mechanisms, clinical links, and precision interventions
- 1Department of Anorectal Surgery, The Gastrointestinal and Anorectal Hospital of Shenyang, Shenyang, Liaoning, China
- 2College of Chemical Science and Technology, Yunnan University, Kunming, China
- 3Department of Integrated Traditional Chinese and Western Medicine, Cardiology, The People's Hospital of Liaoning Province, Shenyang, China
Abstract
Benign anorectal disorders and ulcerative colitis (UC) are typically managed as separate clinical conditions, despite growing recognition of overlapping pathophysiological features. Constipation, hemorrhoidal disease, anal fistula and colonic mucosal inflammation may converge on partially shared molecular pathways involving microbial dysbiosis, altered microbial metabolite generation, epithelial barrier impairment, immune activation, stromal remodeling and dysregulated tissue repair, although the strength of mechanistic evidence varies substantially among these conditions. This review synthesizes advances from the past decade to propose a translational molecular medicine framework for investigating potential molecular connections among anatomically distinct anorectal and colonic disorders, without assuming shared causal origins. Clinical and pathological associations between disordered defecation, hemorrhoidal vascular remodeling, fistula persistence and UC are contextualized alongside current insights into gut and anorectal microbiota dysbiosis, short-chain fatty acid signaling, bile acid metabolism, tryptophan metabolite activity, gas-producing microbial communities, mucus biology, tight junction function, innate and adaptive immune responses, and fibro-inflammatory repair processes. Integrating microbiome profiling, metabolomics, transcriptomics, single-cell and spatial analyses with causal inference provides a cross-disease framework for resolving convergent molecular states associated with recurrence, healing and therapeutic response. By moving beyond disease-by-disease description, this strategy may uncover biomarkers and actionable pathways otherwise overlooked, supporting mechanism-informed prevention, perioperative optimization and individualized intervention across anorectal disorders and inflammatory bowel disease (IBD).
Related
- TMAO at the Crossroads of the Gut–Brain Axis: Emerging Mechanisms Linking Microbiota-Derived Metabolites to Neuroinflammation and Cognitive Dysfunction
- Natural Compounds and Their Microbiota-Derived Metabolites as Modulators of the Microbiota–Gut–Brain Axis in Alzheimer Disease: Biochemical Mechanisms and Drug Discovery Insights—A Narrative Review
- Small-Intestinal Motility Interrelates With Fecal Microbiota, Metabolites and Metabolic Tissue Gene Expression in Metabolic Dysfunction-Associated Steatotic Liver Disease
- Gut microbiota- and probiotic-derived bioactive metabolites: mechanisms, evidence, and therapeutic potential in metabolic disorders
- From gut dysbiosis to synaptic dysfunction in insomnia-associated depression: immune mechanisms and nutritional interventions
BibTeX
@article{yuan2026microbiota,
title = {{Gut microbiota, microbial metabolites, and mucosal barrier dysfunction in benign anorectal disorders and ulcerative colitis: shared mechanisms, clinical links, and precision interventions}},
author = {Hexue Yuan and Maofang Zhao and Yunfen Wang and Chen Shen and Delong Liu and Chunxiao Wang and Jian Liu},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1979206},
url = {https://doi.org/10.3389/fmed.2026.1979206},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut microbiota, microbial metabolites, and mucosal barrier dysfunction in benign anorectal disorders and ulcerative colitis: shared mechanisms, clinical links, and precision interventions
AU - Hexue Yuan
AU - Maofang Zhao
AU - Yunfen Wang
AU - Chen Shen
AU - Delong Liu
AU - Chunxiao Wang
AU - Jian Liu
PY - 2026
DA - 2026/10/12
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1979206
UR - https://doi.org/10.3389/fmed.2026.1979206
AB - Benign anorectal disorders and ulcerative colitis (UC) are typically managed as separate clinical conditions, despite growing recognition of overlapping pathophysiological features. Constipation, hemorrhoidal disease, anal fistula and colonic mucosal inflammation may converge on partially shared molecular pathways involving microbial dysbiosis, altered microbial metabolite generation, epithelial barrier impairment, immune activation, stromal remodeling and dysregulated tissue repair, although the strength of mechanistic evidence varies substantially among these conditions. This review synthesizes advances from the past decade to propose a translational molecular medicine framework for investigating potential molecular connections among anatomically distinct anorectal and colonic disorders, without assuming shared causal origins. Clinical and pathological associations between disordered defecation, hemorrhoidal vascular remodeling, fistula persistence and UC are contextualized alongside current insights into gut and anorectal microbiota dysbiosis, short-chain fatty acid signaling, bile acid metabolism, tryptophan metabolite activity, gas-producing microbial communities, mucus biology, tight junction function, innate and adaptive immune responses, and fibro-inflammatory repair processes. Integrating microbiome profiling, metabolomics, transcriptomics, single-cell and spatial analyses with causal inference provides a cross-disease framework for resolving convergent molecular states associated with recurrence, healing and therapeutic response. By moving beyond disease-by-disease description, this strategy may uncover biomarkers and actionable pathways otherwise overlooked, supporting mechanism-informed prevention, perioperative optimization and individualized intervention across anorectal disorders and inflammatory bowel disease (IBD).
SN - 2296-858X
ER -